Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
View/ Open
Date
2024-07-01Author
Bugazia, DoaaAl-Najjar, Ebtesam
Esmail, Abdullah
Abdelrahim, Saifudeen
Abboud, Karen
Abdelrahim, Adham
Umoru, Godsfavour
Rayyan, Hashem A.
Abudayyeh, Ala
Al Moustafa, Ala Eddin
Abdelrahim, Maen
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of death in the United States and is expected to be ranked second in the next 10 years due to poor prognosis and a rising incidence. Distant metastatic PDAC is associated with the worst prognosis among the different phases of PDAC. The diagnostic options for PDAC are convenient and available for staging, tumor response evaluation, and management of resectable or borderline resectable PDAC. However, imaging is crucial in PDAC diagnosis, monitoring, resectability appraisal, and response evaluation. The advancement of medical technologies is evolving, hence the use of imaging in PDAC treatment options has grown as well as the utilization of ctDNA as a tumor marker. Treatment options for metastatic PDAC are minimal with the primary goal of therapy limited to symptom relief or palliation, especially in patients with low functional capacity at the point of diagnosis. Molecular profiling has shown promising potential solutions that would push the treatment boundaries for patients with PDAC. In this review, we will discuss the latest updates from evidence-based guidelines regarding diagnosis, therapy response evaluation, prognosis, and surveillance, as well as illustrating novel therapies that have been recently investigated for PDAC, in addition to discussing the molecular profiling advances in PDAC.
Collections
- Medicine Research [1474 items ]
Related items
Showing items related by title, author, creator and subject.
-
Magnetic mesoporous nanospheres anchored with LyP-1 as an efficient pancreatic cancer probe
Jiang, Y.; Liu, S.; Zhang, Y; Li, H; He, H.; Dai, J.; Jiang, T.; Ji, W.; Geng, D.; Elzatahry, A.A.; Alghamdi, A.; Fu, D.; Deng, Y.; Zhao, D.; ... more authors ... less authors ( Elsevier Ltd , 2017 , Article)Immobilization of a ligand that selectively interacts with cancer cells to nanomaterials can enhance their diagnostic and therapeutic efficiency. In this study, we firstly demonstrate the high expression of receptor for ... -
Facial Nerve Palsy in Hypertriglyceridemia-Induced Pancreatitis: A Case Report and Literature Review.
Khalil, Sondos K; Khalil, Sulafa K; Al Refai, Fakhreddin; B Yousif, Zahra; Maliyakkal, Abdul Majeed; Madani, Omar Adil A; Musa, Muzamil... more authors ... less authors ( Springer , 2023 , Article)Acute pancreatitis is associated with multiple local or systemic complications in response to systemic inflammation that may eventually result in multi-organ failure. Neurological complications are uncommon in acute ... -
Metabolomic biomarkers of pancreatic cancer: a meta-analysis study
Mehta, Khyati Y.; Wu, Hung-Jen; Menon, Smrithi S.; Fallah, Yassi; Zhong, Xiaogang; Rizk, Nasser; Unger, Keith; Mapstone, Mark; Fiandaca, Massimo S.; Federoff, Howard J.; Cheema, Amrita K.... more authors ... less authors ( Impact Journals , 2017 , Article)Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is no blood test for early detection and diagnosis of this disease. Several research groups have reported on metabolomics based ...